Related Experiment Video
Updated: Apr 26, 2026

Author Spotlight: Improving Radiation Therapy Access with Radiation Planning Assistant
Published on: October 6, 2023
Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric
Philippe Giguère1,2, Houda Bahig1, Sydney Westra3
1Centre de Recherche du Centre Hospitalier de l'Université de Montréal (crCHUM, University of Montreal), 900 Rue Saint-Denis, Montreal, Quebec, H2X0A9, Canada.
Purpose:
Radiotherapy has achieved substantial progress often attributed to accelerated technological innovation over decades. However, randomized controlled trials (RCTs) are costly, difficult to fund and to conduct, such that the generation of quality evidence is outpaced by changes in practice. We sought to evaluate the implementation performance of a platform approach to the conduct of pragmatic RCTs in radiation oncology.
Methods:
We implemented PERa, a platform consisting of a prospective registry of patients receiving standard-of-care radiation therapy, designed to support pragmatic registry-based RCT (rRCT) methods and staged informed consent. Implementation performance metrics included rate of registry enrollment, acceptability of re-contact and/or serving as controls for interventional trials, activation and recruitment of embedded comparative effectiveness rRCTs, compliance to study arms, and completeness of ePRO data acquired at scale.
Results:
Between January 1, 2018 and December 31, 2023, the registry accrued 1415 participants across 5 participating institutions. At time of stage 1 consent, 93% agreed to re-contact for participation in a clinical trial, and 97% consented to serve as control. Seven embedded rRCTs were activated, and one third of participants (n = 477) were randomized. Only two study arm non-compliance events were recorded. Although 97% of subjects consented to ePROs, completion rate was only 53% in those with stage 1 only consent, rising to 62% in those subjects also consented at a second stage to a companion rRCT.
Conclusion:
The PERa platform is met with high acceptance demonstrating efficient conduct of rRCTs embedded in routine radiation oncology practice. Future work to improve ePRO completions and automate harmonization with EMR data lakes have the potential to improve the quality of evidence generation and support learning health systems.
Trial Registration:
NCT03378856: Registered on December 12, 2017. NCT04100174: Registered on September 20, 2019. NCT04178174: Registered on November 17, 2019. NCT05457699: Registered on July 04, 2022. NCT04405401: Registered on May 24, 2020. NCT04901234: Registered on May 17, 2021. NCT05317026: Registered on March 08, 2022.
More Related Videos
06:20Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
Published on: March 11, 2021
07:57Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
Published on: March 24, 2022
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Treatment Resistant Cancers
Radiation: Applications
The average...
Cancer Survival Analysis